Eton Pharmaceuticals (ETON) Stock News
$ETON · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Eton Pharmaceuticals (ETON) in the past 30 days. BORSA’s news read on ETON is bullish at 65/100, based on 1 company event over the past 7 days. ETON last closed at $51.16 on Oct 27, up 1.93% over five sessions and down 13.55% over the past month. Eton Pharmaceuticals’ next earnings report is scheduled for Thursday, Nov 5 after the close.
The wire on $ETON
newest first · updated · direct subject stories onlyEton Pharmaceuticals licensed patent rights from Baylor College of Medicine for mecasermin/IGF-1 in infantile and epileptic spasms. An IND has been submitted for a Phase 2 study in children with refractory epileptic spasms, with first patient dosing targeted for Q1 2027. Preclinical data showed a ~50% reduction in daily spasm counts. Eton retains commercial rights to ET-900.
bullish 70 · impact 35The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Eton Pharmaceuticals (ETON) stock: common questions
What is the latest Eton Pharmaceuticals stock news?
The highest-impact ETON story BORSA published in the past 30 days: